Abstract 3631: United Kingdom lung cancer screening trial (UKLS): First 88897 approaches.

The UK Lung Cancer Screening trial (UKLS) aims to inform decision makers about the desirability of introducing lung cancer population screening in the UK, and to assess mortality and cost effectiveness. The UKLS pilot started recruitment in 2011 at the Liverpool Heart & Chest Hospital and Papworth Hospital, Cambridge. 250,000 individuals were approached, of whom 4000 were identified as at high risk of lung cancer by the Liverpool Lung Project (LLP) validated Risk Prediction Model. Participants randomised to the study arm have a single low dose computed tomography (CT) scan; controls have usual care. We now have data from the first 88,897 people approached. 26.8% responded to the first recruitment questionnaire (‘positive responders’), of whom 12% had a LLP risk score UKLS is the first CT screening RCT to select high risk people using a validated risk prediction model at a population level. Only 5% of clinic attendees were 60 or younger (compared to 47% of all 88,897 approached); this may have implications for cost effectiveness of CT screening. As expected, very few never smokers were at high risk. The response rate and clinic attendance is better in ex-smokers than in current smokers. An understanding of the factors influencing high risk individuals’ uptake of CT screening will be important in developing future CT screening programmes, if adopted. Citation Format: John K. Field, David Baldwin, Anand Devaraj, Kate Brain, Tim Eisen, John Holemans, Martin Ledson, Nicholas Screaton, Robert C. Rintoul, Ghasem Yadegarfar, Chris Hands, Fiona E. McRonald, Kate Lifford, David Whynes, Keith Kerr, Richard Page, Mahesh Parmar, David Weller, David Whynes, Paula Williamson, David Hansell, Stephen W. Duffy. United Kingdom lung cancer screening trial (UKLS): First 88897 approaches. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3631. doi:10.1158/1538-7445.AM2013-3631